Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

312
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
312
Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

775
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
775
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring Equitable Care Delivery: Insights From the Health Equity Report Card (HERC) Pilot in Academic Cancer Centers.

Journal of the National Comprehensive Cancer Network : JNCCNยท2026
Same author

Developing the multidisciplinary and multispecialty workforce and the systems needed to sustain high-quality care from diagnosis through long-term survivorship.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancerยท2026
Same author

TIP26-316: Cultural Adaptation and Validation of the Armenian Version of the NCCN Distress Thermometer.

Journal of the National Comprehensive Cancer Network : JNCCNยท2026
Same author

TIP26-316: Cultural Adaptation and Validation of the Armenian Version of the NCCN Distress Thermometer.

Journal of the National Comprehensive Cancer Network : JNCCNยท2026
Same author

Re-Envisioning Electronic Health Records to Optimize Patient-Centered Cancer Care, Quality, Surveillance, and Research.

JCO oncology practiceยท2024
Same author

NCCN Policy Summit: Reducing the Cancer Burden Through Prevention and Early Detection.

Journal of the National Comprehensive Cancer Network : JNCCNยท2023

Related Experiment Video

Updated: Feb 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Developments in Molecular Testing and Biosimilars.

Katy Winckworth-Prejsnar, Elizabeth A Nardi, Lisa Korin Lentz

    Journal of the National Comprehensive Cancer Network : JNCCN
    |June 10, 2017
    PubMed
    Summary

    Molecular diagnostics and biosimilars can improve cancer care access and lower costs, but challenges remain in ensuring safe, effective, and affordable treatments. Understanding policy and regulatory guidance is crucial for integrating these innovations into oncology.

    More Related Videos

    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
    10:35

    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

    Published on: April 5, 2018

    10.8K
    Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
    07:43

    Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

    Published on: July 14, 2023

    2.9K

    Related Experiment Videos

    Last Updated: Feb 28, 2026

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
    07:25

    In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

    Published on: May 4, 2017

    18.3K
    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
    10:35

    A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

    Published on: April 5, 2018

    10.8K
    Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
    07:43

    Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices

    Published on: July 14, 2023

    2.9K

    Area of Science:

    • Oncology
    • Healthcare Policy
    • Biotechnology

    Background:

    • Molecular testing and biosimilars present opportunities for enhanced cancer treatment accessibility and cost reduction.
    • However, significant challenges exist in ensuring patient access to innovative therapies while maintaining safety, efficacy, and affordability.

    Framework:

    • The National Comprehensive Cancer Network (NCCN) convened a policy summit in September 2016.
    • The summit addressed critical issues and opportunities within molecular testing and biosimilar landscapes in oncology.

    Implementation:

    • Discussions focused on the current status and future trajectory of molecular diagnostics and biosimilars in cancer care.
    • Keynote speakers and panelists explored the regulatory guidance and policy implications impacting their use.

    Implications:

    • Addressing patient access and education needs is vital for the successful integration of these advancements.
    • Navigating the complexities of molecular testing appropriateness and biosimilar clinical application is essential for healthcare systems.